$1.85
+0.01 (+0.54%)
Open$1.85
Previous Close$1.84
Day High$1.90
Day Low$1.81
52W High$16.00
52W Low$1.71
Volume—
Avg Volume424.0K
Market Cap48.36M
P/E Ratio—
EPS$-2.18
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,631.9% upside
Current
$1.85
$1.85
Target
$32.04
$32.04
$22.50
$32.04 avg
$35.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.29M | 31.67M | 27.66M |
| Net Income | 4.35M | 5.71M | 3.74M |
| Profit Margin | 13.5% | 18.0% | 13.5% |
| EBITDA | 8.33M | 8.25M | 7.51M |
| Free Cash Flow | 3.02M | 4.79M | 4.27M |
| Rev Growth | +12.6% | +22.6% | -0.7% |
| Debt/Equity | 0.19 | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |